Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia

被引：2
|
作者：
El Kinge, Abdul Rahman
Hatourn, Hassan A.
Mahfouz, Rami A. [2 ]
Otrock, Zaher K. [2 ]
Jabbour, Elias [3 ]
Kantarjian, Hagop [3 ]
Bazarbachi, Ali [1 ]
机构：
[1] Amer Univ Beirut, Med Ctr, Dept Internal Med, Bone Marrow Transplantat Program, Beirut, Lebanon
[2] Amer Univ Beirut, Med Ctr, Dept Pathol & Lab Med, Beirut, Lebanon
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷 / 04期
关键词：
ACUTE MYELOGENOUS LEUKEMIA; RELAPSE; CHEMOTHERAPY; PROPOSAL;
D O I：
10.1016/j.leukres.2008.05.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：565 / 566
页数：2
相关论文
共 50 条
  • [1] Post-remission therapy for acute myeloid leukemia
    Schlenk, Richard F.
    HAEMATOLOGICA, 2014, 99 (11) : 1663 - 1670
  • [2] Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia
    Walter, Roland B.
    Medeiros, Bruno C.
    Powell, Bayard L.
    Schiffer, Charles A.
    Appelbaum, Frederick R.
    Estey, Elihu H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (05): : 739 - 742
  • [3] Post-remission therapy of acute myeloid leukemia in first remission
    Kim, ST
    Kim, K
    Lee, SH
    Kim, WS
    Jung, CW
    Lee, MH
    Park, K
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 59 - 59
  • [4] Race and intensity of post-remission therapy in acute myeloid leukemia
    Brady, Anna K.
    Fu, Alex Z.
    Earl, Marc
    Kalaycio, Matt
    Advani, Anjali
    Saunthararajah, Yogen
    Sobecks, Ronald
    Copelan, Edward
    Sekeres, Mikkael A.
    LEUKEMIA RESEARCH, 2011, 35 (03) : 346 - 350
  • [5] Gemtuzumab ozogamicin in acute myeloid leukemia
    Godwin, C. D.
    Gale, R. P.
    Walter, R. B.
    LEUKEMIA, 2017, 31 (09) : 1855 - 1868
  • [6] Gemtuzumab ozogamicin for acute myeloid leukemia
    Appelbaum, Frederick R.
    Bernstein, Irwin D.
    BLOOD, 2017, 130 (22) : 2373 - 2376
  • [7] Gemtuzumab ozogamicin in acute myeloid leukemia
    C D Godwin
    R P Gale
    R B Walter
    Leukemia, 2017, 31 : 1855 - 1868
  • [8] Gemtuzumab Ozogamicin in Combination with Vorinostat and Azacitidine As Induction and Post-Remission Therapy in Older Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): A Phase 1 Study
    Walter, Roland B.
    Medeiros, Bruno C.
    Gardner, Kelda M.
    Estey, Elihu H.
    BLOOD, 2011, 118 (21) : 670 - 670
  • [9] PHASE 2 TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH GEMTUZUMAB OZOGAMICIN AS INDUCTION AND POST-REMISSION THERAPY IN OLDER PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA (AML)
    Walter, B.
    Medeiros, B.
    Nielsen-Stoeck, M.
    Harrington, E.
    Powell, B.
    Schiffer, C.
    Appelbaum, F.
    Estey, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 29 - 30
  • [10] Race and Intensity of Post-Remission Therapy in Acute Myeloid Leukemia (AML).
    Brady, Anna K.
    Fu, Alex Z.
    Earl, Marc
    Kalaycio, Matt
    Advani, Anjali
    Saunthararajah, Yogen
    Sobecks, Ronald
    Copelan, Edward
    Sekeres, Mikkael A.
    BLOOD, 2009, 114 (22) : 419 - 419
12345